A Phase I, Open-Label, Cohort Study of Multiple Doses of Cavatak™ (Coxsackie Virus A21) Given Intravenously to Stage IV Solid Tumour Cancer Patients Bearing ICAM-1 With or Without DAF Expressing Tumours (PSX-X04)
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2018
At a glance
- Drugs CVA 21 (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Malignant melanoma; Prostate cancer; Solid tumours
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 09 Apr 2013 Primary endpoint `patient tolerability' has been met, according to a Viralytics media release.
- 09 Apr 2013 Results reported in a Viralytics media release.